INVVY News and Press, Indivior PLC ADR From 05/22/23

Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl PR Newswire In the 12-month period ending in December 2022 , over 79,000 people in the U...

2023-04-29 07:56:06 ET Indivior PLC (INVVY) Q1 2023 Earnings Conference Call April 27, 2023 08:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Offi...

2023-04-28 02:06:35 ET The following slide deck was published by Indivior PLC in conjunction with their 2023 Q1 earnings call. For further details see: Indivior PLC 2023 Q1 - Results - Earnings Call Presentation

Indivior Announces Q1 2023 Financial Results PR Newswire SLOUGH, U.K. , and Richmond, Va. , April 27, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023 . The earnings release, inv...

Indivior To Participate In Bank of America Global Healthcare Conference 2023 PR Newswire SLOUGH, UK and RICHMOND, Va. , April 25, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that it will participate in the following investor event: ...

2023-04-07 08:09:06 ET Summary Opioid treatment provider Indivior has seen a 20%+ price rise in 2023, but its latest financials are not supportive. The company swung into a loss for FY22 on the provision for litigation, which is a red flag, considering that these costs could mount...

Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc. PR Newswire Combination Strengthens Indivior's Addiction Treatment and Science Portfolio RICHMOND, Va. , March 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) ("Indivior" or the "Company") to...

The following slide deck was published by Indivior PLC in conjunction with their 2023 Q4 earnings call. For further details see: Indivior PLC 2023 Q4 - Results - Earnings Call Presentation

Indivior PLC (INVVY) Q4 2022 Earnings Conference Call February 16, 2023 08:00 ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Officer Ryan Preblick - Chief...

Indivior PLC ADR press release ( OTCPK:INVVY ): Q4 Non-GAAP EPS of $0.27. Revenue of $241M (+8.6% Y/Y). Guidance: TotalFY2023expectedNRrangeof$950Mto$1,020M(+9%vs.FY2022atthemid-point),reflectingcontinued strongSUBLOCADEandPERSERISgrowthandacceleratedshareerosionforUSSUBOXONEF...